Employers should keep in mind that indication-based coverage decisions (such as covering GLP-1 drugs for diabetes treatment but not for treatment of obesity or other conditions, such as addiction) can potentially raise concerns under the Americans with Disabilities Act (ADA), the ACA, HIPAAs nondiscrimination requirements, or the Mental Health Parity and Addiction Equity Act, among other laws
Cellular communication pathway analysis Metabolic signaling research models Mitochondrial peptide behavior studies Because of its higher concentration, MOTS-C supports consistent evaluation across multiple test conditions and helps researchers maintain a steady approach as studies progress
While GLP-1 medications like Ozempic, Wegovy, and Zepbound are effective for weight loss, rapid fat reduction can sometimes lead to changes in body appearance that some patients find undesirable
PMID 17699297
Direct effects on milk supply have not been studied in humans
CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing